Aging, rather than Parkinson's disease, affects the responsiveness of PBMCs to the immunosuppression of bone marrow mesenchymal stem cells

Guan,Yun‑Qian; Zhao,Chun‑Song; Zou,Hai‑Qiang; Yan,Xiao‑Ming; Luo,Lu‑Lu; Wu,Jia‑Lin; Li,Xiaobo; Zhang,Yu Alex

doi:10.3892/mmr.2018.9670

Aging, rather than Parkinson's disease, affects the responsiveness of PBMCs to the immunosuppression of bone marrow mesenchymal stem cells

Authors:
- Yun‑Qian Guan
- Chun‑Song Zhao
- Hai‑Qiang Zou
- Xiao‑Ming Yan
- Lu‑Lu Luo
- Jia‑Lin Wu
- Xiaobo Li
- Yu Alex Zhang
View Affiliations

Affiliations: Department of Cell Biology, Key laboratory of Ministry of Education, Xuanwu Hospital, Capital Medical University, Beijing 100053, P.R. China, Department of Neurology, The General Hospital of Guangzhou Military Command, Guangzhou, Guangdong 510010, P.R. China, Department of Function Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, P.R. China, Department of Neurology, Northern Jiangsu People's Hospital, Clinical Medical School of Yangzhou University, Yangzhou, Jiangsu 225009, P.R. China
Published online on: November 19, 2018 https://doi.org/10.3892/mmr.2018.9670
Pages: 165-176
Copyright: © Guan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Whether aging or Parkinson's disease (PD) affects the responses of peripheral blood mononuclear cells (PBMCs) to immunosuppression by bone marrow‑derived mesenchymal stem cell (BM‑MSCs) and which cytokines are more effective in inducing BM‑MSCs to be immunosuppressive remains to be elucidated. PBMCs were isolated from healthy young (age 26‑35), healthy middle‑aged (age 56‑60) and middle‑aged PD‑affected individuals. All the recruits were male. The mitogen‑stimulated PBMCs and proinflammatory cytokine‑pretreated BM‑MSCs were co‑cultured. The PBMC proliferation was measured using Cell Counting Kit‑8, while the cytokine secretion was assayed by cytometric bead array technology. The immunosuppressive ability of BM‑MSCs was confirmed in young healthy, middle‑aged healthy and middle‑aged PD‑affected individuals. Among the three groups, the PBMC proliferation and cytokine secretion of the young healthy group were suppressed more significantly compared with those of the middle‑aged healthy and middle‑aged PD‑affected group. No significant differences were identified in the PBMC proliferation and cytokine secretion between the patients with PD and the middle‑aged healthy subjects. Interferon (IFN)‑γ synergized with tumor necrosis factor (TNF)‑α, interleukin (IL)‑1α or IL‑1β was more effective than either one alone, and the combinations of IFN‑γ + IL‑1α and IFN‑γ + IL‑1β were more effective than IFN‑γ + TNF‑α in inducing BM‑MSCs to inhibit PBMC proliferation. The results of the present study suggested that aging, rather than PD, affects the response of PBMCs toward the suppression of BM‑MSC, at least in middle‑aged males. Patients with PD aged 56‑60 remain eligible for anti‑inflammatory BM‑MSC‑based therapy. Treatment of BM‑MSCs with IFN‑γ + IL‑1α or IFN‑γ + IL‑1β prior to transplantation may result in improved immunosuppressive effects.

View Figures

View References

1	Hirsch EC and Hunot S: Neuroinflammation in Parkinson's disease: A target for neuroprotection? Lancet Neurol. 8:382–397. 2009. View Article : Google Scholar : PubMed/NCBI
2	Stone DK, Reynolds AD, Mosley RL and Gendelman HE: Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid Redox Signal. 11:2151–2166. 2009. View Article : Google Scholar : PubMed/NCBI
3	McGeer PL, Itagaki S, Boyes BE and McGeer EG: Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 38:1285–1291. 1988. View Article : Google Scholar : PubMed/NCBI
4	Hughes V: Microglia: The constant gardeners. Nature. 485:570–572. 2012. View Article : Google Scholar : PubMed/NCBI
5	Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T and Torizuka T: Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol. 57:168–175. 2005. View Article : Google Scholar : PubMed/NCBI
6	Long-Smith CM, Sullivan AM and Nolan YM: The influence of microglia on the pathogenesis of Parkinson's disease. Prog Neurobiol. 89:277–287. 2009. View Article : Google Scholar : PubMed/NCBI
7	Marinova-Mutafchieva L, Sadeghian M, Broom L, Davis JB, Medhurst AD and Dexter DT: Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: A time course study in a 6-hydroxydopamine model of Parkinson's disease. J Neurochem. 110:966–975. 2009. View Article : Google Scholar : PubMed/NCBI
8	Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, et al: Infiltration of CD4⁺ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest. 119:182–192. 2009.PubMed/NCBI
9	Ferrari CC and Tarelli R: Parkinson's disease and systemic inflammation. Parkinsons Dis. 2011:4368132011.PubMed/NCBI
10	Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, et al: Structural and functional features of central nervous system lymphatic vessels. Nature. 523:337–341. 2015. View Article : Google Scholar : PubMed/NCBI
11	Farkas E, De Jong GI, de Vos RA, Jansen Steur EN and Luiten PG: Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease. Acta Neuropathol. 100:395–402. 2000. View Article : Google Scholar : PubMed/NCBI
12	Odoardi F, Sie C, Streyl K, Ulaganathan VK, Schläger C, Lodygin D, Heckelsmiller K, Nietfeld W, Ellwart J, Klinkert WE, et al: T cells become licensed in the lung to enter the central nervous system. Nature. 488:675–679. 2012. View Article : Google Scholar : PubMed/NCBI
13	Wang G, Zhang J, Hu X, Zhang L, Mao L, Jiang X, Liou AK, Leak RK, Gao Y and Chen J: Microglia/macrophage polarization dynamics in white matter after traumatic brain injury. J Cereb Blood Flow Metab. 33:1864–1874. 2013. View Article : Google Scholar : PubMed/NCBI
14	Arimoto T, Choi DY, Lu X, Liu M, Nguyen XV, Zheng N, Stewart CA, Kim HC and Bing G: Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiol Aging. 28:894–906. 2007. View Article : Google Scholar : PubMed/NCBI
15	Feng ZH, Wang TG, Li DD, Fung P, Wilson BC, Liu B, Ali SF, Langenbach R and Hong JS: Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett. 329:354–358. 2002. View Article : Google Scholar : PubMed/NCBI
16	Vijitruth R, Liu M, Choi DY, Nguyen XV, Hunter RL and Bing G: Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J Neuroinflammation. 3:62006. View Article : Google Scholar : PubMed/NCBI
17	Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M and Ringdén O: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 363:1439–1441. 2004. View Article : Google Scholar : PubMed/NCBI
18	Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, et al: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet. 371:1579–1586. 2008. View Article : Google Scholar : PubMed/NCBI
19	Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S and Gianni AM: Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 99:3838–3843. 2002. View Article : Google Scholar : PubMed/NCBI
20	Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi GL, Pistoia V and Uccelli A: Human mesenchymal stem cells modulate B-cell functions. Blood. 107:367–372. 2006. View Article : Google Scholar : PubMed/NCBI
21	Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC and Moretta L: Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: Role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 111:1327–1333. 2008. View Article : Google Scholar : PubMed/NCBI
22	Laranjeira P, Gomes J, Pedreiro S, Pedrosa M, Martinho A, Antunes B, Ribeiro T, Santos F, Domingues R, Abecasis M, et al: Human bone marrow-derived mesenchymal stromal cells differentially inhibit cytokine production by peripheral blood monocytes subpopulations and myeloid dendritic cells. Stem Cells Int. 2015:8190842015. View Article : Google Scholar : PubMed/NCBI
23	Yoo KH, Jang IK, Lee MW, Kim HE, Yang MS, Eom Y, Lee JE, Kim YJ, Yang SK, Jung HL, et al: Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol. 259:150–156. 2009. View Article : Google Scholar : PubMed/NCBI
24	Grozdanov V, Bliederhaeuser C, Ruf WP, Roth V, Fundel-Clemens K, Zondler L, Brenner D, Martin-Villalba A, Hengerer B, Kassubek J, et al: Inflammatory dysregulation of blood monocytes in Parkinson's disease patients. Acta Neuropathol. 128:651–663. 2014. View Article : Google Scholar : PubMed/NCBI
25	Calligaris R, Banica M, Roncaglia P, Robotti E, Finaurini S, Vlachouli C, Antonutti L, Iorio F, Carissimo A, Cattaruzza T, et al: Blood transcriptomics of drug-naive sporadic Parkinson's disease patients. BMC Genomics. 16:8762015. View Article : Google Scholar : PubMed/NCBI
26	Chen L, Mo M, Li G, Cen L, Wei L, Xiao Y, Chen X, Li S, Yang X, Qu S and Xu P: The biomarkers of immune dysregulation and inflammation response in Parkinson disease. Transl Neurodegener. 5:162016. View Article : Google Scholar : PubMed/NCBI
27	Annesley SJ, Lay ST, De Piazza SW, Sanislav O, Hammersley E, Allan CY, Francione LM, Bui MQ, Chen ZP, Ngoei KR, et al: Immortalized Parkinson's disease lymphocytes have enhanced mitochondrial respiratory activity. Dis Model Mech. 9:1295–1305. 2016. View Article : Google Scholar : PubMed/NCBI
28	Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC and Shi Y: Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2:141–150. 2008. View Article : Google Scholar : PubMed/NCBI
29	Li X, Du W, Ma FX, Feng X, Bayard F and Han ZC: High concentrations of TNF-α induce cell death during interactions between human umbilical cord mesenchymal stem cells and peripheral blood mononuclear cells. PLoS One. 10:e01286472015. View Article : Google Scholar : PubMed/NCBI
30	Wu T, Liu J, Zhang HJ, Hallett M, Zheng Z and Chan P: Attention to automatic movements in Parkinson's disease: Modified automatic mode in the striatum. Cerebral Cortex. 25:3330–3342. 2015. View Article : Google Scholar : PubMed/NCBI
31	Bech P, Allerup P, Larsen ER, Csillag C and Licht RW: The Hamilton Depression Scale (HAM-D) and the Montgomery-Åsberg Depression Scale (MADRS). A psychometric re-analysis of the European genome-based therapeutic drugs for depression study using Rasch analysis. Psychiatry Res. 217:226–232. 2014. View Article : Google Scholar : PubMed/NCBI
32	Li W, Ren G, Huang Y, Su J, Han Y, Li J, Chen X, Cao K, Chen Q, Shou P, et al: Mesenchymal stem cells: A double-edged sword in regulating immune responses. Cell Death Differ. 19:1505–1513. 2012. View Article : Google Scholar : PubMed/NCBI
33	Asanuma M and Miyazaki I: Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease? Exp Neurol. 206:172–178. 2007. View Article : Google Scholar : PubMed/NCBI
34	Samii A, Etminan M, Wiens MO and Jafari S: NSAID use and the risk of Parkinson's disease: Systematic review and meta-analysis of observational studies. Drugs Aging. 26:769–779. 2009. View Article : Google Scholar : PubMed/NCBI